Monoclonal Antibodies—Therapeutic and Diagnostic Uses in Malignancy

Por Lowder, James N., Levy, Ronald
Publicado em 1985

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies

Por Xu, Cong, Goggin, Timothy K., Su, Xiang‐Yao, Taverna, Pietro, Oganesian, Aram, Lowder, James N., Azab, Mohammad, Kantarjian, Hagop
Publicado no CPT Pharmacometrics Syst Pharmacol (2017)

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

Por Dutcher, Janice P, Schwartzentruber, Douglas J, Kaufman, Howard L, Agarwala, Sanjiv S, Tarhini, Ahmad A, Lowder, James N, Atkins, Michael B
Publicado no J Immunother Cancer (2014)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

Por Wong, Michael K, Daniels, Gregory A, Kaufman, Howard L, McDermott, David F, Morse, Michael A, Aung, Sandra, Lowder, James N
Publicado em 2013

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

Por Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A
Publicado em 2014

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

Por Kaufman, Howard L., Wong, Michael K., Daniels, Gregory A., McDermott, David F., Aung, Sandra, Lowder, James N., Morse, Michael A.
Publicado no J Pers Med (2014)

Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy

Por Fazio, Carolina, Covre, Alessia, Cutaia, Ornella, Lofiego, Maria Fortunata, Tunici, Patrizia, Chiarucci, Carla, Cannito, Sara, Giacobini, Gianluca, Lowder, James N., Ferraldeschi, Roberta, Taverna, Pietro, Di Giacomo, Anna Maria, Coral, Sandra, Maio, Michele
Publicado no Front Pharmacol (2018)

SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clini...

Por Crabb, Simon, Danson, Sarah J., Catto, James W. F., McDowell, Cathy, Lowder, James N., Caddy, Joshua, Dunkley, Denise, Rajaram, Jessica, Ellis, Deborah, Hill, Stephanie, Hathorn, David, Whitehead, Amy, Kalevras, Mihalis, Huddart, Robert, Griffiths, Gareth
Publicado no Trials (2018)

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomized, dose-escalation phase 1 study

Por Issa, Jean-Pierre J., Roboz, Gail, Rizzieri, David, Jabbour, Elias, Stock, Wendy, O’Connell, Casey, Yee, Karen, Tibes, Raoul, Griffiths, Elizabeth A., Walsh, Katherine, Daver, Naval, Chung, Woonbok, Naim, Sue, Taverna, Pietro, Oganesian, Aram, Hao, Yong, Lowder, James N., Azab, Mohammad, Kantarjian, Hagop
Publicado no Lancet Oncol (2015)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

Por Roboz, Gail J., Kantarjian, Hagop M., Yee, Karen W. L., Kropf, Patricia L., O'Connell, Casey L., Griffiths, Elizabeth A., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Walsh, Katherine J., Rizzieri, David, Lunin, Scott D., Curio, Tania, Chung, Woonbok, Hao, Yong, Lowder, James N., Azab, Mohammad, Issa, Jean‐Pierre J.
Publicado no Cancer (2017)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Por Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Publicado no Cancer Immunol Immunother (2016)